These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 34790354)

  • 1. Immunohistochemistry as an accurate tool for the assessment of
    Rusu S; Verocq C; Trepant AL; Maris C; De Nève N; Blanchard O; Van Campenhout C; De Clercq S; Rorive S; Cotoi OS; Decaestecker C; Salmon I; D'Haene N
    Mol Clin Oncol; 2021 Dec; 15(6):270. PubMed ID: 34790354
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Accurate detection of BRAF p.V600E mutations in challenging melanoma specimens requires stringent immunohistochemistry scoring criteria or sensitive molecular assays.
    Fisher KE; Cohen C; Siddiqui MT; Palma JF; Lipford EH; Longshore JW
    Hum Pathol; 2014 Nov; 45(11):2281-93. PubMed ID: 25228337
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Utility and evaluation of immunohistochemical detection of BRAF V600E mutation in melanoma].
    Lyu JJ; Kong YY; Cai X; Shen XX; Lu YW; Ren M
    Zhonghua Bing Li Xue Za Zhi; 2017 Aug; 46(8):548-552. PubMed ID: 28810295
    [No Abstract]   [Full Text] [Related]  

  • 4. Specific immunohistochemical detection of the BRAF V600E mutation in primary and metastatic papillary thyroid carcinoma.
    Zhu X; Luo Y; Bai Q; Lu Y; Lu Y; Wu L; Zhou X
    Exp Mol Pathol; 2016 Feb; 100(1):236-41. PubMed ID: 26795218
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A mutant BRAF V600E-specific immunohistochemical assay: correlation with molecular mutation status and clinical outcome in colorectal cancer.
    Day F; Muranyi A; Singh S; Shanmugam K; Williams D; Byrne D; Pham K; Palmieri M; Tie J; Grogan T; Gibbs P; Sieber O; Waring P; Desai J
    Target Oncol; 2015 Mar; 10(1):99-109. PubMed ID: 24859797
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Microfluidic-Based Immunohistochemistry Combined With Next-Generation Sequencing on Diagnostic Tissue Sections for Detection of Tumoral BRAF V600E Mutation.
    Leblond AL; Rechsteiner M; Jones A; Brajkovic S; Dupouy D; Soltermann A
    Am J Clin Pathol; 2019 Jun; 152(1):59-73. PubMed ID: 31065676
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Utility of BRAF V600E Immunohistochemistry Expression Pattern as a Surrogate of BRAF Mutation Status in 154 Patients with Advanced Melanoma.
    Tetzlaff MT; Pattanaprichakul P; Wargo J; Fox PS; Patel KP; Estrella JS; Broaddus RR; Williams MD; Davies MA; Routbort MJ; Lazar AJ; Woodman SE; Hwu WJ; Gershenwald JE; Prieto VG; Torres-Cabala CA; Curry JL
    Hum Pathol; 2015 Aug; 46(8):1101-10. PubMed ID: 26058727
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospective evaluation of two screening methods for molecular testing of metastatic melanoma: Diagnostic performance of BRAF V600E immunohistochemistry and of a NRAS-BRAF fully automated real-time PCR-based assay.
    Vallée A; Denis-Musquer M; Herbreteau G; Théoleyre S; Bossard C; Denis MG
    PLoS One; 2019; 14(8):e0221123. PubMed ID: 31415669
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunohistochemistry as a reliable method for detection of BRAF-V600E mutation in melanoma: a systematic review and meta-analysis of current published literature.
    Anwar MA; Murad F; Dawson E; Abd Elmageed ZY; Tsumagari K; Kandil E
    J Surg Res; 2016 Jun; 203(2):407-15. PubMed ID: 27363650
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of high resolution melting analysis, pyrosequencing, next generation sequencing and immunohistochemistry to conventional Sanger sequencing for the detection of p.V600E and non-p.V600E BRAF mutations.
    Ihle MA; Fassunke J; König K; Grünewald I; Schlaak M; Kreuzberg N; Tietze L; Schildhaus HU; Büttner R; Merkelbach-Bruse S
    BMC Cancer; 2014 Jan; 14():13. PubMed ID: 24410877
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunohistochemistry is highly sensitive and specific for the detection of V600E BRAF mutation in melanoma.
    Long GV; Wilmott JS; Capper D; Preusser M; Zhang YE; Thompson JF; Kefford RF; von Deimling A; Scolyer RA
    Am J Surg Pathol; 2013 Jan; 37(1):61-5. PubMed ID: 23026937
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of BRAF p.V600E Mutations in Melanoma by Immunohistochemistry Has a Good Interobserver Reproducibility.
    Marin C; Beauchet A; Capper D; Zimmermann U; Julié C; Ilie M; Saiag P; von Deimling A; Hofman P; Emile JF
    Arch Pathol Lab Med; 2014 Jan; 138(1):71-5. PubMed ID: 23651150
    [TBL] [Abstract][Full Text] [Related]  

  • 13. VE1 immunohistochemistry is an adjunct tool for detection of BRAF
    Rashid FA; Tabassum S; Khan MS; Ansari HR; Asif M; Sheikh AK; Sameer Aga S
    J Clin Lab Anal; 2021 Feb; 35(2):e23628. PubMed ID: 33305405
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunohistochemistry with the anti-BRAF V600E (VE1) antibody: impact of pre-analytical conditions and concordance with DNA sequencing in colorectal and papillary thyroid carcinoma.
    Dvorak K; Aggeler B; Palting J; McKelvie P; Ruszkiewicz A; Waring P
    Pathology; 2014 Oct; 46(6):509-17. PubMed ID: 25014730
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of Five Different Assays for the Detection of BRAF Mutations in Formalin-Fixed Paraffin Embedded Tissues of Patients with Metastatic Melanoma.
    Franczak C; Salleron J; Dubois C; Filhine-Trésarrieu P; Leroux A; Merlin JL; Harlé A
    Mol Diagn Ther; 2017 Apr; 21(2):209-216. PubMed ID: 28130756
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor homogeneity between primary and metastatic sites for BRAF status in metastatic melanoma determined by immunohistochemical and molecular testing.
    Boursault L; Haddad V; Vergier B; Cappellen D; Verdon S; Bellocq JP; Jouary T; Merlio JP
    PLoS One; 2013; 8(8):e70826. PubMed ID: 23976959
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Utilization of a MAB for BRAF(V600E) detection in papillary thyroid carcinoma.
    Bullock M; O'Neill C; Chou A; Clarkson A; Dodds T; Toon C; Sywak M; Sidhu SB; Delbridge LW; Robinson BG; Learoyd DL; Capper D; von Deimling A; Clifton-Bligh RJ; Gill AJ
    Endocr Relat Cancer; 2012 Dec; 19(6):779-84. PubMed ID: 22997209
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BRAF(V600E) and NRAS(Q61L/Q61R) mutation analysis in metastatic melanoma using immunohistochemistry: a study of 754 cases highlighting potential pitfalls and guidelines for interpretation and reporting.
    Kakavand H; Walker E; Lum T; Wilmott JS; Selinger CI; Smith E; Saw RP; Yu B; Cooper WA; Long GV; O'Toole SA; Scolyer RA
    Histopathology; 2016 Oct; 69(4):680-6. PubMed ID: 27151331
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Performance comparison of three BRAF V600E detection methods in malignant melanoma and colorectal cancer specimens.
    Løes IM; Immervoll H; Angelsen JH; Horn A; Geisler J; Busch C; Lønning PE; Knappskog S
    Tumour Biol; 2015 Feb; 36(2):1003-13. PubMed ID: 25318602
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BRAF
    Yakout NM; Abdallah DM; Abdelmonsif DA; Kholosy HM; Talaat IM; Elsakka O
    Cancer Cell Int; 2023 Feb; 23(1):17. PubMed ID: 36737739
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.